Jiangsu Aidea Pharmaceutical Co Ltd (688488) — Working Capital to Net Assets Ratio
Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a Working Capital to Net Assets ratio of 30.9% as of March 2026. Working capital of CN¥337.02 Million (current assets of CN¥1.01 Billion minus current liabilities of CN¥675.68 Million) is measured against net assets of CN¥1.09 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Jiangsu Aidea Pharmaceutical Co Ltd (688488) liquidity interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Jiangsu Aidea Pharmaceutical Co Ltd Working Capital to Net Assets (2016–2025)
This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of March 2026, the ratio stands at 30.9%, reflecting working capital of CN¥337.02 Million against net assets of CN¥1.09 Billion CNY. For the complete balance sheet picture, see Jiangsu Aidea Pharmaceutical Co Ltd total assets.
Annual Working Capital to Net Assets for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 688488 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 21.4% | CN¥229.53 Million | CN¥1.07 Billion | CN¥938.74 Million | CN¥709.21 Million | ▼ -1.7 pp |
| 2024 | 23.0% | CN¥245.87 Million | CN¥1.07 Billion | CN¥894.93 Million | CN¥649.06 Million | ▼ -10.8 pp |
| 2023 | 33.8% | CN¥380.81 Million | CN¥1.13 Billion | CN¥872.38 Million | CN¥491.57 Million | ▼ -5.4 pp |
| 2022 | 39.3% | CN¥470.78 Million | CN¥1.20 Billion | CN¥802.46 Million | CN¥331.68 Million | ▼ -16.8 pp |
| 2021 | 56.1% | CN¥734.39 Million | CN¥1.31 Billion | CN¥826.93 Million | CN¥92.54 Million | ▼ -12.6 pp |
| 2020 | 68.7% | CN¥933.72 Million | CN¥1.36 Billion | CN¥1.01 Billion | CN¥73.00 Million | ▲ +40.1 pp |
| 2019 | 28.6% | CN¥158.99 Million | CN¥556.24 Million | CN¥368.11 Million | CN¥209.13 Million | ▲ +2.7 pp |
| 2018 | 25.9% | CN¥135.25 Million | CN¥522.71 Million | CN¥310.36 Million | CN¥175.11 Million | ▼ -7.5 pp |
| 2017 | 33.4% | CN¥171.66 Million | CN¥514.09 Million | CN¥305.07 Million | CN¥133.42 Million | ▲ +21.0 pp |
| 2016 | 12.3% | CN¥37.09 Million | CN¥300.40 Million | CN¥167.05 Million | CN¥129.96 Million | — |